Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report)’s stock price was up 2.6% during trading on Monday . The stock traded as high as $4.49 and last traded at $4.34. Approximately 774,289 shares were traded during mid-day trading, an increase of 34% from the average daily volume of 579,686 shares. The stock had previously closed at $4.23.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a report on Wednesday, November 22nd.
Black Diamond Therapeutics Stock Performance
Hedge Funds Weigh In On Black Diamond Therapeutics
Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in Black Diamond Therapeutics during the second quarter worth about $76,000. Rock Springs Capital Management LP acquired a new stake in Black Diamond Therapeutics during the 2nd quarter worth approximately $2,844,000. Artal Group S.A. boosted its position in Black Diamond Therapeutics by 24.3% in the 2nd quarter. Artal Group S.A. now owns 2,046,517 shares of the company’s stock valued at $10,335,000 after buying an additional 400,000 shares during the period. Candriam S.C.A. acquired a new position in shares of Black Diamond Therapeutics in the second quarter worth $2,525,000. Finally, VR Adviser LLC acquired a new position in shares of Black Diamond Therapeutics in the second quarter worth $1,786,000.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.
- Five stocks we like better than Black Diamond Therapeutics
- How to Invest in Small Cap Stocks
- 3 attractive stocks that insiders are buying
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.